Medical Centre Hungarian Defence Forces
- Address
- Podmaniczky Utca 109, 1062 Budapest, Hungary
Neoplasms
The Medical Centre Hungarian Defence Forces in Budapest is conducting research focused on advanced cancer therapies, aiming to improve survival and quality of life for patients with hard‑to‑treat tumors. Trials explore novel targeted agents, immunotherapy combinations, and biomarker‑driven approaches across several tumor types.
- Targeted therapy for gastrointestinal stromal tumors
- Immunotherapy plus hormonal treatment for metastatic prostate cancer
- HER2‑directed treatment strategies for urothelial carcinoma
- Neoadjuvant immunotherapy for resectable head and neck squamous cell carcinoma
- Innovative agents for advanced solid tumors
The department supports 12 active clinical trials with 9 investigators, reflecting a strong commitment to oncology research.
Digestive System Diseases
Research at the centre addresses disorders of the gastrointestinal tract, seeking safer and more effective treatments for chronic inflammatory conditions and tumor‑related complications. Studies evaluate oral and injectable therapies that aim to reduce disease activity and prevent progression.
- New oral agents for ulcerative colitis
- Molecularly driven therapies for gastrointestinal stromal tumors
- Biomarker‑guided strategies in digestive cancers
- Combination regimens to improve mucosal healing
- Patient‑reported outcome measures in chronic gut diseases
The site’s multidisciplinary team integrates gastroenterology expertise to advance therapeutic options for patients across the digestive system.
Eye Diseases
The department’s ophthalmology program evaluates cutting‑edge ocular therapies, with the goal of preserving vision and reducing retinal damage. Trials test gene‑based treatments and anti‑vascular agents to address age‑related degeneration and vascular complications.
- Intravitreal gene therapy for geographic atrophy
- Anti‑VEGF strategies for macular edema secondary to retinal vein occlusion
- Long‑acting delivery systems for retinal diseases
- Comparative studies of dosing intervals for ocular injections
- Safety assessments of novel ocular biologics
These studies contribute to the development of treatments that can halt or reverse vision loss in patients with serious eye conditions.
Musculoskeletal Diseases
Investigations into joint and connective‑tissue disorders focus on biologic therapies that modulate immune pathways, aiming to reduce inflammation and improve functional outcomes for people with arthritis.
- Biologic modulation of joint inflammation in psoriatic arthritis
- Dose‑optimization studies for new anti‑inflammatory agents
- Combination approaches with existing disease‑modifying drugs
- Imaging biomarkers to track treatment response
- Quality‑of‑life assessments in musculoskeletal trials
The research supports the development of therapies that can provide lasting relief for patients with chronic musculoskeletal pain.
Bacterial Infections and Mycoses
Although fewer studies are listed in this area, the centre maintains capacity to evaluate antimicrobial and antifungal agents, emphasizing safety and efficacy in vulnerable patient groups.
- Exploratory trials of new antibacterial compounds
- Safety profiling of antifungal therapies in immunocompromised patients
- Pharmacokinetic studies of novel infection‑control drugs
- Diagnostic biomarker validation for resistant infections
- Integrated stewardship programs within the hospital setting
Ongoing collaboration with infectious‑disease specialists ensures readiness to launch additional studies as new agents become available.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Seagen Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Centre Hungarian Defence Forces
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2018-12-13 | 2019-08-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.